Independent guides and reviews on peptide skincare, anti-aging treatments, and aesthetic trends.
Eli Lilly’s retatrutide Phase 3 results have brought fresh attention to an investigational treatment targeting three hormone receptors involved in metabolic regulation. In results announced on 23 July 2026, Lilly reported average weight reductions of up to 22.6% across two additional late-stage trials. The studies, TRIUMPH-2 and TRIUMPH-3, evaluated different…
BPC-157 is widely discussed in peptide clinics, fitness communities and online recovery forums. It is often promoted alongside claims about tissue repair, digestive health and exercise recovery. But those claims can blur an important distinction: an interesting research compound is not the same as a treatment proven safe and effective…
Cura Peptide Hair Growth Serum reviews raise a question worth asking before buying: does an ingredient list containing five peptides translate into convincing evidence for hair growth? The formula does list five peptide ingredients, but that is different from demonstrating that the finished serum treats hair loss. The central issue…
Searching for a cagrilintide retatrutide metabolic outcomes study can lead to a misleading impression: that these two investigational compounds have been tested together or directly compared. The supplied research references do not identify such a study. Instead, they describe separate development programmes from rival pharmaceutical companies, with different treatments, trial…
Eloralintide is Lilly’s investigational, once-weekly injectable amylin-analogue peptide, being studied as a potential treatment for obesity and related metabolic conditions. Formerly known as LY3841136, it is a selective amylin receptor agonist—not an approved medicine. Its clinical development has attracted attention because of substantial weight reductions reported in phase 2 research…
Interest in KPV peptide benefits has grown alongside broader curiosity about peptides and inflammation research. Online discussions often connect KPV with gut health, skin care, and immune signaling. However, those discussions can blur an important distinction: a biological effect observed in an experimental setting is not the same as a…
Eli Lilly retatrutide Phase 3 data have drawn attention for the scale of weight loss reported across the TRIUMPH clinical trial program. In the supplied results, average weight loss reached 28.3% at 80 weeks in TRIUMPH-1, while a smaller extension group had a reported average reduction of 30.3% at 104…
The cagrilintide and retatrutide metabolic outcomes study raises an important research question: could two investigational approaches to metabolic regulation offer complementary effects? But understanding the evidence starts with a distinction that should not get lost in headlines. The combination study published in Nature Metabolism was preclinical research conducted in obese…
CBL-514 is an experimental injection that kills fat cells in the specific spot where it is injected. It is not approved anywhere in the world, and it is not a peptide — two facts that most of what you will read about it right now gets wrong. US search interest…
DSIP peptide, short for delta sleep-inducing peptide, has attracted interest among people looking for new approaches to sleep problems, stress, recovery and overall wellbeing. First identified in the 1970s, DSIP is a naturally occurring peptide that has been studied for its possible effects on sleep regulation and the body’s response…